Figure 3

Efficacy of PSTi8 as compared to metformin. Acute PSTi8 (i.p, 5 mg/kg), chronic PSTi8 (i.p, 2 mg/kg for 7 days), acute metformin (p.o, 300 mg/kg) and chronic metformin (p.o, 300 mg/kg for 7 days) administration (30 min before bolus glucose/insulin) during i.p GTT (1 g/kg) or ITT (0.6 IU/kg) in fasting (6 h) HFrD mice (n = 6). (a) i.pGTT with acute metformin and PSTi8; (b) i.pGTT with chronic metformin and PSTi8; (c) i.p ITT with acute metformin and PSTi8; (d) i.p ITT with chronic metformin and PSTi8; (e) AUC of i.p GTT with acute metformin and PSTi8; (f) AUC of i.p GTT with chronic metformin and PSTi8; (g) AUC of i.p ITT with acute metformin and PSTi8; (h) AUC of i.p ITT with chronic metformin and PSTi8. α, HFrD mice vs drug treatment, β, chronic metformin vs chronic PSTi8 treatment. Glucose reduction experiment after acute administration of PSTi8 (i.p, 5 mg/kg) and metformin (p.o, 300 mg/kg) (i) C57BL/6J mice and (j) db/db mice. (k) Plasma concentration vs time profile of PSTi8 following intraperitoneal administration at dose of 5 mg/kg to db/db mice. Met: metformin *^,#P < 0.05; **^,##P < 0.01; ***^,###P < 0.001. Error bar indicate mean ± s.e.m.